^
Association details:
| Biomarker: | CD28 overexpression |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Poteligeo (mogamulizumab-kpkc) (CCR4 receptor antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinicopathological significance of CD28 overexpression in adult T-cell leukemia/lymphoma
Published date:
11/05/2021
Excerpt:
In the entire ATLL patient cohort, CD28 overexpressers showed a significantly poorer overall survival (OS), compared to non-overexpressers (P=0.001). The same was true for a subgroup who were treated with multidrug regimens with or without mogamulizumab.
DOI:
10.1111/cas.15191
